Simona Lamba
University of Turin · 162 works · 7,497 citations · h-index 32
Top works
- IDH1mutations at residue p.R132 (IDH1R132) occur frequently in high-grade gliomas but not in other solid tumors
- Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
- Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
- Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer
- Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes
- AKT1E17K in human solid tumours
- EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
- Novel Somatic and Germline Mutations in Cancer Candidate Genes in Glioblastoma, Melanoma, and Pancreatic Carcinoma
- The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma
- Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses
- Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
- The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
- Adaptive mutability of colorectal cancers in response to targeted therapies
- KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy
- Mutational Profile of GNAQQ209 in Human Tumors
- The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone
- High-dose vitamin C enhances cancer immunotherapy
- RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells